To determine whether a threshold of a 1-h glucose challenge test (GCT) eliminates the need for a 3-h glucose tolerance test (GTT). STUDY DESIGN: A retrospective cohort of patients undergoing GTT after GCT was ⩾ 140 mg dl − 1 . Gestational diabetes mellitus (GDM) was diagnosed using National Diabetes Data Group (NDDG) and Carpenter-Coustan (CC) criteria. Sensitivity, specificity and predictive values were calculated for 1-h GCT values of 160 to 220 mg dl − 1 . RESULT: Of 6218 patients, 988 (15.9%) had an elevated GCT and 753 (12.1%) underwent a GTT. In all, 165 (2.7%) were diagnosed with GDM using NDDG criteria, and 250 (4.0%) by CC criteria. The positive predictive value of a 1-h of GCT ⩾ 200 mg dl − 1 for GDM was 68.6% by NDDG and 80.0% for GDM by CC criteria. CONCLUSION: Although the predictive value of an elevated 1-h ⩽ 200 mg dl − 1 for GDM was high, 1 in 3 to 1 in 5 women would be overdiagnosed with GDM if the 3-h GTT was omitted.
INTRODUCTION
Gestational diabetes mellitus (GDM) is a common complication of pregnancy, affecting nearly 6% of all pregnancies. 1 Various screening strategies for GDM exist. The American College of Obstetricians and Gynecologists recommends a 2-step screening process, using a 50-g glucose challenge test (GCT) for screening, followed by a diagnostic 3-h glucose tolerance test (GTT) using 100 g of glucose for those individuals with 1-h glucose levels ⩾ 130 to 140 mg dl − 1 . 1 Two main diagnostic criteria can be used for the diagnosis of GDM, the National Diabetes Data Group (NDDG) criteria or the more stringent lower thresholds of the Carpenter-Coustan (CC) criteria. Although use of the CC criteria results in approximately 50% more diagnoses of GDM, neither criteria has been shown to more favorably improve pregnancy outcomes and both are acceptable in current clinical practice. 1 Some studies suggested that women with a very high 1-h GCT might not need a 3-h GTT to diagnose GDM. [2] [3] [4] [5] As would be expected, higher 1-h GCT thresholds result in lower sensitivity but increased specificity and decreased false positive rates in diagnosing GDM. However, the positive predictive value of an extremely elevated 1-h GCT has varied widely across studies, ranging from 50 to 95% for a threshold of 180 mg dl − 1 in some reports and from 79 to 100% for a threshold of 200 mg dl − 1 or greater in others. [2] [3] [4] [5] [6] [7] [8] [9] These studies are limited by their small sample sizes, by the use of single-ethnicity populations and by the lack of contemporary data evaluating this question.
Because current data are unclear, there are varied clinical practices regarding patients with extremely elevated 1-h results, with some institutions managing those patients as diabetics without further testing and others proceeding with the 3-h GTT for definitive diagnosis. 3 Although forgoing the 3-h GTT in those with a very high 1-h could allow for earlier treatment of GDM, eliminate the inconvenience and cost of the additional test and avoid extremely elevated blood glucose levels induced by a 3-h GTT, it could also lead to over diagnosis with unnecessary treatment of those who would not actually have GDM based on 3-h testing.
Our aim was to estimate whether a threshold of a 1-h GCT, alone or in combination with maternal risk factors, could achieve high enough specificity and positive predictive value to eliminate the need for a 3-h GTT.
METHODS
This was a retrospective cohort study of all consecutive patients undergoing a 1-h, 50-g GCT at Barnes Jewish Hospital between 2004 and 2008. Women were included in the study if they had a singleton gestation, did not have Type I or Type II diabetes and completed 1-h GCT testing followed by 3-h GTT testing as appropriate after 20 weeks gestation. Women were excluded if there were no 3-h GTT values available in the medical record. The study was conducted after approval from the Washington University School of Medicine Human Research Protection Office. Given the retrospective nature of the study, the need for informed consent was waived.
Our University-based tertiary care center employs a policy of universal GDM screening. Screening was conducted between 24 and 28 weeks unless risk factors suggested need for earlier testing, although only those with testing performed after 20 weeks were included for this analysis. Risk factors leading to early testing included a history of previous GDM, obesity with body mass index (BMI) ⩾ 30.0 kg m −2 , history of macrosomic infant in a prior pregnancy, first-degree relative with diabetes mellitus or glycosuria. For women with a normal early 1-h GCT, screening was repeated between 24 and 28 weeks and only the second was included for analysis. For those with an elevated 1-h GCT of ⩾ 140 mg dl − 1 , prompt diagnostic testing with a 3-h GTT was completed, generally within 1 week of initial screening test. GDM was diagnosed by having two or more abnormal values using NDDG criteria (fasting ⩾ 105 mg dl ).
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Information on maternal baseline characteristics, obstetric history, including prior gestational diabetes (based on patient report or available medical records from prior pregnancy), medical history of comorbid conditions that are associated with GDM, BMI at time of presentation to prenatal care and laboratory data was obtained from the prenatal record.
Descriptive statistics were used to characterize the cohort. Baseline characteristics and outcomes were compared between women with and without an extremely elevated 1 h. As originally suggested by Carpenter and Coustan, an extremely elevated 1 h was defined as ⩾ 180 mg dl − 1 .
2
Student's t-test or Mann-Whitney U-test was used for continuous variables, and chi-squared tests were used for dichotomous variables as appropriate with a two-sided alpha of 0.05 considered as significant. For continuous variables, normality was tested using histogram technique and confirmed using the Kolmogorov-Smirnoff test. One-hour GCT results were then categorized by 20 mg dl − 1 increments between 160 and 220 mg dl − 1 . Receiver Operating Characteristic (ROC) curve analysis was used to evaluate the test characteristic. The c-statistic, or area under the curve (AUC), is used to evaluate the efficacy of screening tests, with AUC approaching 1.0 and the far left corner of an ROC graph for more effective tests, and AUC paralleling the diagonal and nearing 0.5 for tests that are not better than chance. 9 The AUC was calculated for each of the thresholds between 160 and 220 mg dl − 1 for the 1-h GCT to diagnose GDM using both CC and NDDG thresholds. The optimal cutpoint was identified using the Youden index, which maximizes the sum of sensitivity and specificity. 10 Sensitivity, specificity, positive and negative predictive values were also calculated for each of the thresholds. Analysis was then repeated for each of the thresholds among women with individual and combinations of specific risk factors, including maternal BMI ⩾ 30 kg m −2 , history of GDM and maternal age. These calculations were performed for both NDDG and CC criteria for diagnosis of GDM. All statistical analyses were performed using STATA 12, special edition (STATA, College Station, TX, USA).
RESULTS
Of 6218 women screened, 988 (15.9%) had an elevated 1-h GCT and 5230 (84.1%) did not ( Figure 1 ). Of the 988 women with an elevated 1 h, 235 (23.8%) were excluded, with 152 (15.3%) lost to follow-up and 59 (6.0%) patients treated as GDM without a 3-h GCT based on provider preference (Figure 1 ). The cohort was 51.3% African American, 33.6% Caucasians, 8.0% Hispanic and 5.0% Asian (Figure 1 ). Of the eligible 753 women with an elevated 1 h, 165 women, or 2.7% of the total cohort, were diagnosed with GDM by NDDG criteria, and 250 (4.0%) were diagnosed with GDM by CC criteria. This increase of GDM in our cohort by 51.5% using the more inclusive CC criteria is similar to other published results. 11 Women with an extremely elevated 1 h of ⩾ 180 mg dl − 1 were similar with respect to race, BMI, history of chronic hypertension, and alcohol, tobacco and drug use to those with a 1 h between 140 and 180 mg dl − 1 groups (Table 1) . Women with an extremely elevated 1 h of ⩾ 180 mg dl − 1 were more likely to be older than 30 (relative risk 1.52, 95% CI 1.05, 2.21) and more likely to have a history of GDM (relative risk 3.48, 95% CI 2.40, 5.02) than those with a 1 h between 140 and 180 mg dl − 1 (Table 1) . ROC analysis was used to evaluate the predictive ability of a 1-h GCT to detect GDM by both NDDG and CC criteria in the cohort of women with elevated 1-h results (Figures 2 and 3) . The AUC was for 0.730 for GDM as diagnosed by NDDG criteria and 0.693 for CC criteria, with the Youden maximal cutpoint 157.5 mg dl − 1 for NDDG criteria and 158.5 mg dl − 1 for CC criteria (Figures 2 and 3) . Analysis was performed for each 20 mg dl − 1 threshold between 160 and 220 mg dl − 1 with increasing specificity, decreasing sensitivity, at each threshold using both NDDG and CC criteria ( Table 2) . As evidenced by the non-overlapping 95% confidence intervals (CIs), these changes in sensitivity and specificity were statistically significant moving from 160 to 180 mg dl − 1 and to 200 mg dl (Table 2) . Additionally, the AUC decreased at each threshold, although the AUC was not significantly different from one another based on the 95% CIs. The specificity increased at higher thresholds, ranging from 92.2 to 99.6% for values from 180 to 220 mg dl − 1 using both diagnostic criteria ( Table 2 ). The positive predictive values also increased at each threshold, ranging from 52.1% at 180 mg dl − 1 to 72.7% at 220 mg dl − 1 using NDDG criteria (Table 3) . Positive predictive Figure 1 . Study population. Study population, with included and excluded participants undergoing the glucose challenge test (GCT) with subsequent glucose tolerance test (GTT). CC, Carpenter-Coustan; NDDG, National Diabetes Data Group.
values were higher using CC criteria, ranging from 64.6% at 180 mg dl − 1 to 81.8% at 200 mg dl − 1 ( Table 3 ). The predictive characteristics of each threshold were evaluated in women with individual and combinations of specific risk factors. Diagnostic performance of each threshold was evaluated in women with the addition of clinical risk factors for GDM, including age over 30, history of GDM and obesity (Table 3) . For each threshold among women with high-risk characteristics, sensitivities and specificities were similar for both criteria. The positive predictive values increased for each threshold in the higher risk subgroups, with the most significant improvements in predictive value coming with the addition of history of GDM, and nominal increases in predictive value with the addition of other characteristics (Table 3) . When considering women who were obese (BMI ⩾ 30.0 kg m ) in addition to being older than age 30 and having a history of GDM, the positive predictive value at 180 mg dl − 1 increased to 82.6% for GDM as diagnosed by NDDG criteria and 91.3% for GDM as diagnosed by CC criteria ( Table 3 ). The positive predictive value increased to 100% for those with a history of GDM and an elevated 1 h of ⩾ 220 mg dl −1 , but this included only seven women in our cohort, yielding a wide 95% CI (Table 3) .
DISCUSSION
In an institution that employs universal GDM screening, we found that even with extremely elevated 1-h GCT results from 180 to 220 mg dl − 1 , the positive predictive values ranged from 52.1 to 81.8%. The predictive value of an extremely elevated 1-h GCT was not substantially improved by applying CC criteria although the CC criteria did predictably increase the rates of diagnosis of GDM. The addition of maternal characteristics that place women at higher risk of GDM improved the positive predictive value to 100%, but only for those with a 1-h result of ⩾ 220 mg dl . These results suggest that a 3-h GTT should be performed even in the setting of an extremely elevated 1-h GCT to avoid over diagnosis and treatment of GDM in those who might not need it. Although Carpenter and Coustan described a greater than 95% positive predictive value for GDM in those patients with elevated 1 h ⩾ 182 mg dl − 1 , subsequent studies have found mixed results. 2 Bobrowski et al., 6 Friedman et al. 4 and Landy et al. 7 found a 100% positive predictive value for GDM with elevated 1-h results greater than 220, 200 and 220 mg dl − 1 , respectively. Our positive predictive values are more similar to the contrasting findings of Shivvers and Lucas, 8 who found that only 81% of those with a 1-h greater than 200 mg dl − 1 were ultimately diagnosed with GDM. Figure 2 . Receiver operating characteristic (ROC) curve for 1-h glucose challenge test (GCT) to predict gestational diabetes mellitus (GDM) using National Diabetes Data Group (NDDG) criteria for 753 participants. Sensitivity, false positive rate and area under the receiver operating curve for the prediction of GDM based on the 1-h GCT using NDDG criteria for diagnosis of GDM, with Youden cutpoint identified. Figure 3 . Receiver operating characteristic (ROC) curve for 1-h glucose challenge test (GCT) to predict gestational diabetes mellitus (GDM) using Carpenter-Coustan (CC) criteria for 753 participants. Sensitivity, false positive rate and area under the receiver operating curve for the prediction of GDM based on the 1-h GCT using CC criteria for diagnosis of GDM, with Youden cutpoint identified.
Similarly, Yogev et al. 3 found that only 34% of Mexican-Americans with 1-h results ⩾ 200 mg dl − 1 had GDM. Some of these studies have been limited by small sample size, which has precluded the statistical approach used in the current study. Most of the studies only evaluate the 1-h with use of the higher thresholds of the NDDG criteria. Additionally, the studies of Yogev et al. 3 and Friedman et al. 4 were in single ethnic populations, limiting their generalizability to multi-ethnic populations such as ours. 3, 4 Finally, other studies are largely based on databases from the 1990s, with the most recent including data from 2004. Given the intervening rise in obesity as well as rates of gestational diabetes, our results add evidence on the predictive value of an extremely elevated 1 h in a more modern cohort.
This study has several strengths. It is a large, diverse cohort of patients with elevated 1-h GCT results. Additionally, the overall prevalence of GDM in our cohort, which was 2.7% using NDDG criteria and 4.0% using CC criteria, shows our prevalence to be in the range of findings from other studies, where estimates for prevalence of GDM in the United States range from 2.0 to 14% depending on which criteria are used. 11 This makes our data externally generalizable to populations with similar GDM prevalence and similar ethnic make-up. Additionally, we attempted to use maternal clinical and demographic data to provide more robust and clinically relevant prediction of the diagnosis of GDM and compared these predictive criteria with both diagnostic approaches currently used in the United States.
Nevertheless, this study is not without limitations. First, it is based on an available retrospective cohort at our institution from 2004 to 2008. Although this represents older data, guidelines for GDM diagnosis at our institution have not changed since that time. Second, 235 people or nearly 24% of those with elevated 1-h GCT were excluded. These included some patients lost to followup as well as 59 (6.0%) patients who were treated for GDM without further diagnostic testing. As expected, these included patients with extremely elevated 1-h GCT results; 43 (4.6%) patients had a 1-h GCT of ⩾ 180 mg dl − 1 . However, in a sensitivity analysis comparing those with an extremely elevated 1 h who were treated as GDM without further testing to those who underwent traditional 3-h testing and were not diagnosed with GDM, there were no significant differences in baseline characteristics between the two groups. Nevertheless, the inclusion of these patients, had they undergone diagnostic testing and tested positive for GDM, likely would have increased the predictive values of an extremely elevated 1-h result. Including these patients as if they all tested positive for GDM raises the predictive value of a 1-h GCT of ⩾ 180 mg dl − 1 to 66.9% using NDDG criteria and 75.5% using CC criteria. Additionally, even in this large cohort, having an extremely elevated 1-h result was still a relatively rare event. The group with high-risk characteristics for whom the 1-h result was 100% predictive included only seven women. These results may not be applicable to a population with a much higher prevalence of women with extremely elevated 1-h GCTs or with a much higher prevalence of GDM. It further should be noted that significant hyperglycemia ⩾ 250 mg dl − 1 occurred during diagnostic testing of 10 patients with a 1-h GCT of ⩾ 200 mg dl − 1 who were subsequently diagnosed with GDM. This hyperglycemia would have been avoided if no further testing had been performed on patients with fasting blood glucose on the day of the 3-h GTT test ⩾ 120 mg dl − 1 . Finally, the current study does not address pregnancy outcomes in women with an extremely elevated 1-h GCT. Previous studies have shown that GDM is associated with higher rates of pregnancy induced hypertension, cesarean deliveries, operative deliveries, shoulder dystocia and macrosomia. 1 Additionally, the Hyperglycemia and Adverse Pregnancy Outcome Study confirmed a continuous relationship between maternal glucose levels and Table 2 . Selected test characteristics for 283 participants with 1-h GCT ⩾ 160 mg dl − 1 using 1-h GCT values, maternal BMI, age over 30 and history of adverse pregnancy outcomes including cesarean delivery and macrosomia. 12 Therefore, some have suggested that those with an extremely elevated 1-h result may have some degree of glucose intolerance and may benefit from treatment for GDM. 7 Further study is needed to evaluate pregnancy outcomes in those with an extremely elevated 1 h who do not have GDM on diagnostic testing.
Despite these limitations, our study adds to the literature by demonstrating that even with an extremely elevated 1-h GCT result of ⩾ 200 mg dl − 1 , 20 to 33% of patients would be overdiagnosed with GDM if the 3-h GTT was omitted. Although the addition of maternal risk factors marginally improves the specificity and positive predictive value of an extremely elevated 1 h, it would only eliminate the need for a 3-h GTT in a few select patients, making this less practical. These findings support the need for a diagnostic 3-h GTT even in those patients with extremely elevated 1-h results.
